Etiome, Cellarity and Empress Therapeutics are being combined into one new AI-aided drugmaker claiming to possess the ability ...
RFK Jr. has given notice that the agency won’t take enforcement action on six peptides that controversially won a contested ...
The highest dose of retatrutide beat Ozempic on measures of blood sugar and weight loss, but was also associated with higher ...
Lilly intends to merge its U.S. and international divisions when a top executive retires. Elsewhere, Astellas closed in on ...
The plan builds on recent FDA moves to speed "personalized" treatments by offering an approval framework for therapies ...
At one of the year’s premiere meetings for cancer research, melanoma vaccine data hailed by scientists sparked a share ...
The buyout hands Ferring rights to a technology capable of simplifying the lengthy and burdensome process of in vitro ...
The latest installment in BioPharma Dive’s data visualization series features a look at the emerging popularity of RNAi ...
Early CDMO engagement can be valuable, particularly when it helps development teams understand technical requirements, ...
Armed with a $300 million financing and two GLP-1 and amylin-targeting medicines, Corxel is set to become the latest weight ...
Novo failed to prove that Lilly’s campaign — which featured claims of obesity drug superiority — meaningfully harmed the Danish company’s sales, a federal judge ruled.
Fresh off a $150 million IPO, Tom Miller spoke to BioPharma Dive about the roadshow process and how he sees AI’s role in drug ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results